Handok, Mitsubishi Tanabe announces licensing agreement for novel DPP-4 agent

Published: 2012-02-02 06:59:00

Updated: 2012-02-02 06:59:00

Handok Pharma and Mitsubishi Tanabe Pharma announced Tuesday the execution of a license agreement granting Hanmi to market Mitsubishi Tanabe’s new dipeptidyl peptidase 4 (DPP-4 agent) MP-513 (teneligliptin) for the treatment of type 2 diabetes.

Under the agreement, Handok will carry out clinical trials and fulfill regulatory procedures so that it may launch MP-513 in Korea by 2015.

Taken ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.